Technical Analysis for PIRS - Pieris Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 0.21 | 24.26% | 0.04 |
Earnings due: Mar 27
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
Crossed Above 50 DMA | Bullish | 0.00% | |
Expansion Breakout | Bullish Swing Setup | 0.00% | |
Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Volume Surge | Other | 0.00% | |
Wide Range Bar | Range Expansion | 0.00% | |
BB Squeeze Ended | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Gapped Up | Strength | 0.00% |
Alert | Time |
---|---|
200 DMA Resistance | about 18 hours ago |
10x Volume Pace | about 18 hours ago |
10 DMA Support | about 20 hours ago |
60 Minute Opening Range Breakout | about 21 hours ago |
Possible Pocket Pivot | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/27/2024
Pieris Pharmaceuticals, Inc. Description
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. It is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Inflammatory Diseases Kidney Disease Dialysis Asthma Sarcoma Carcinoma Membrane Technology Hepatology Chronic Kidney Disease End Stage Renal Disease Renal Disease Blood Plasma Kidney Stage Renal Disease Central Nervous System Tumors Hepcidin Iron Deficiency
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.52 |
52 Week Low | 0.1361 |
Average Volume | 510,206 |
200-Day Moving Average | 0.27 |
50-Day Moving Average | 0.17 |
20-Day Moving Average | 0.17 |
10-Day Moving Average | 0.18 |
Average True Range | 0.02 |
RSI (14) | 70.85 |
ADX | 18.18 |
+DI | 43.84 |
-DI | 9.38 |
Chandelier Exit (Long, 3 ATRs) | 0.22 |
Chandelier Exit (Short, 3 ATRs) | 0.21 |
Upper Bollinger Bands | 0.19 |
Lower Bollinger Band | 0.15 |
Percent B (%b) | 1.46 |
BandWidth | 23.31 |
MACD Line | 0.00 |
MACD Signal Line | 0.00 |
MACD Histogram | 0.0027 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.37 | ||||
Resistance 3 (R3) | 0.37 | 0.33 | 0.34 | ||
Resistance 2 (R2) | 0.33 | 0.29 | 0.32 | 0.33 | |
Resistance 1 (R1) | 0.27 | 0.26 | 0.30 | 0.26 | 0.32 |
Pivot Point | 0.22 | 0.22 | 0.24 | 0.22 | 0.22 |
Support 1 (S1) | 0.16 | 0.18 | 0.19 | 0.16 | 0.10 |
Support 2 (S2) | 0.12 | 0.16 | 0.11 | 0.09 | |
Support 3 (S3) | 0.06 | 0.12 | 0.08 | ||
Support 4 (S4) | 0.05 |